Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Linnea I. Chap"'
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we rep
Externí odkaz:
https://doaj.org/article/b14be29b81754bafad04d4aa37714251
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/4ff05e79a58f49b980db63215fe0a4b3
Autor:
Elizabeth Claire Dees, Adrian Crijanovschi, Carolien P. Schröder, Maia Gogiladze, Boris Krastev, Marina Maglakelidze, Mark D. Pegram, Catharina Wilhelmina Menke, Agnes Jager, Patrick Neven, Philippe Aftimos, Ramsha Iqbal, Susanna Varkey Ulahannan, Sarika Jain, Dinara Ryspayeva, Linnea I. Chap, Massimo Cristofanilli, Jorianne Boers, Erika Hamilton, Iurie Bulat
Publikováno v:
Journal of Clinical Oncology. 39:1063-1063
1063 Background: Rintodestrant, a potent, oral selective estrogen receptor degrader, competitively binds and degrades the estrogen receptor (ER), thus blocking ER signaling in tumors resistant to other endocrine therapies (ET). Results from parts 1 a
Autor:
Carolyn C. Nienstedt, Eva Ciruelos, Linnea I. Chap, Nikos Sophos, Stephen Chia, Chinjune Lin, Giulia Bianchi, William Jacot, Nicholas C. Turner, Dejan Juric, Ursa Brown-Glaberman, Manuel Ruiz Borrego, Hope S. Rugo, Antonia Ridolfi
Publikováno v:
Journal of Clinical Oncology. 36:TPS1107-TPS1107
TPS1107Background: Endocrine therapy (ET) is the standard of care for treatment of HR+, HER2– aBC. However, ET resistance occurs frequently due to dysregulation of the PI3K/AKT/mTOR pathway, specif...
Publikováno v:
American Journal of Clinical Oncology. 20:505-508
We report the case of a patient with a rare miliary variant of osteosarcoma associated with symptomatic hypocalcemia and review the literature regarding the pathogenesis of multifocal osteosarcoma, treatment options, and the associated hypocalcemia.
Autor:
James D. Reimann, P. Kelly Marcom, Maura N. Dickler, Virginia K. Langmuir, Frankie A. Holmes, Melody A. Cobleigh, Louis Fehrenbacher, Linnea I. Chap, Beth Overmoyer, Kathy D. Miller, Hope S. Rugo, Amy P. Sing
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(4)
Purpose This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients with metastatic breast cancer previously treated with an an